0 additive manufacturing companies serving the Bioprinting & Tissue Engineering industry, tracked by AMPulse. Browse profiles, funding rounds, and technology details.
Updated
Additive manufacturing in Bioprinting & Tissue Engineering is the use of additive manufacturing to deposit living cells, biomaterials, and bio-inks to construct tissue and organ-like structures for research, drug discovery, and emerging therapeutic applications.
Why AM fits Bioprinting & Tissue Engineering: Bioprinting is the longest-tail AM application: predominantly research-stage today, but with credible therapeutic potential by 2030. Drug discovery (3D tissue models replacing 2D cell cultures), regenerative medicine (cartilage and skin grafts), and personalized cancer treatment screening are the near-term commercial applications.
Common AM processes: extrusion bioprinting, inkjet bioprinting, laser-induced forward transfer (LIFT), VPP with bioink. Typical materials: hydrogels (alginate, collagen, gelatin methacrylate), living cells, growth factors, decellularized extracellular matrix.
Additive manufacturing in Bioprinting & Tissue Engineering is the use of additive manufacturing to deposit living cells, biomaterials, and bio-inks to construct tissue and organ-like structures for research, drug discovery, and emerging therapeutic applications.
AMPulse tracks 0 companies serving the Bioprinting & Tissue Engineering vertical. Leading examples by funding include various companies tracked by AMPulse.
Bioprinting & Tissue Engineering most commonly uses extrusion bioprinting, inkjet bioprinting, laser-induced forward transfer (LIFT), VPP with bioink. Typical materials include hydrogels (alginate, collagen, gelatin methacrylate), living cells, growth factors, decellularized extracellular matrix.
Bioprinting is the longest-tail AM application: predominantly research-stage today, but with credible therapeutic potential by 2030. Drug discovery (3D tissue models replacing 2D cell cultures), regenerative medicine (cartilage and skin grafts), and personalized cancer treatment screening are the near-term commercial applications.